

10 August 2007

REGEN THERAPEUTICS PLC
("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Tigran Kalaydjian

4. Full name of shareholder(s) (if difference from 3):

Unokal Ltd
Clariant Foundation

5. Date of the transaction and date on which the threshold is crossed or reached (v):

8 August 2007

6. Date on which issued notified:

9 August 2007

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code	GB0004468319
Situation Previous to the triggering transaction (vi) –	
Number of Shares	30,000,000
Number of Voting Rights (viii)	30,000,000
Resulting situation after the triggering transaction (viii) –	
Number of Shares	31,000,000
Number of Voting Rights – Direct (x)	N/A
Number of Voting Rights – Indirect (xi)	31,000,000
% of voting rights – Direct	N/A
% of voting rights – Indirect	3.02

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument	N/A
Expiration date (xiii)	N/A
Exercise/Conversion Period/Date (xiv)	N/A
Number of voting rights that may be acquired if the instrument is exercised/converted	N/A
% of voting rights	N/A
Total (A+B)	
Number of voting rights	31,000,000
% of voting rights	3.02

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

Unokal Ltd
Clariant Foundation

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A
13. Additional information:	N/A
14. Contact name:	N/A
15. Contact telephone number:	N/A

For further information:

Andrew Marshall
Greycoat Communications
Tel: +44 (0) 207 960 6007
Mobile: +44 (0) 7785 297111

Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 153 4920

Andrew Baker / Cecil Jordaan / Rory Creedon

HB-Corporate
Tel:

+44(0) 207 510 8600